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CXCL12 inhibits expression of the NMDA receptor’s
NR2B subunit through a histone deacetylasedependent pathway contributing to neuronal survival
J Nicolai1, S Burbassi1, J Rubin2 and O Meucci*,1,3

Homeostatic chemokines, such as CXCL12, can affect neuronal activity by the regulation of inhibitory and excitatory
neurotransmission, but the mechanisms involved are still undeﬁned. Our previous studies have shown that CXCL12 protects
cortical neurons from excitotoxicity by promoting the function of the gene-repressor protein Rb, which is involved in the
recruitment of chromatin modiﬁers (such as histone deacetylases (HDACs)) to gene promoters. In neurons, Rb controls activitydependent genes essential to neuronal plasticity and survival, such as the N-methyl-D-aspartic acid (NMDA) receptor’s subunit
NR2B, the expression of which in the tetrameric ion channel largely affects calcium signaling by glutamate. In this study, we
report that CXCL12 differentially modulates intracellular responses after stimulation of synaptic and extrasynaptic NMDA
receptors, by a speciﬁc regulation of the NR2B gene that involves HDACs. Our results show that CXCL12 selectively inhibits
NR2B expression in vitro and in vivo altering NMDA-induced calcium responses associated with neuronal death, while
promoting prosurvival pathways that depend on stimulation of synaptic receptors. Along with previous studies, these ﬁndings
underline the role of CXCL12/CXCR4 in the regulation of crucial components of glutamatergic transmission. These novel effects
of CXCL12 may be involved in the physiological function of the chemokine in both developing and mature brains.
Cell Death and Disease (2010) 1, e33; doi:10.1038/cddis.2010.10; published online 1 April 2010
Subject Category: Neuroscience
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits distribution and reproduction
in any medium, provided the original author and source are credited. This license does not permit commercial exploitation without speciﬁc
permission.

Chronic neurodegenerative and neuroinﬂammatory conditions
share common characteristics of neuronal dysfunction and
cell death involving energy failure and excessive extracellular
excitatory neurotransmitters.1,2 Increased concentrations of
excitatory neurotransmitters can result in the overstimulation
of membrane receptors leading to high intracellular calcium
levels, a hallmark of excitotoxicity.3 Glutamate, the primary
excitatory neurotransmitter, activates various metabotropic as
well as ionotropic receptors, including the a-amino-3-hydroxyl5-methyl-4-isoxazole-propionate (AMPA), Kainate, and
N-methyl-D-aspartic acid (NMDA) receptors, all of which are
involved in and are required for physiological synaptic
transmission.4 However, overactivation of these receptors
may contribute to neurotoxicity in pathological conditions
because of inappropriate activation of downstream signaling
pathways. Of these excitatory receptors, NMDA receptors
have a large role in excitotoxic cell death mostly due to their
high calcium conductance and low rate of desensitization.5,6
NMDA receptors are heteromeric ligand-gated ion channels
composed of two obligatory NR1 subunits, and two regulatory

subunits (NR2A-D or NR3 A-B).7 The functional properties
of the receptor depend on the subunit combination, which
regulates synaptic maturation, neuronal plasticity, and survival. Expression of the regulatory subunits is developmentally
and spatially regulated and inﬂuences the channel kinetics.8
Several studies have indicated that in mature neurons,
NR2B-containing receptors are predominantly, although not
exclusively, located extrasynaptically9,10 and that calcium
inﬂux depends on relative NR2B expression, as NR2B confers
a slower decay time to the receptor.11 Neurons respond differently depending on the characteristics of calcium changes,
including the magnitude of calcium rise, spatial and temporal
properties, and the channel initiating calcium responses.12
Therefore, NMDA receptors located at synaptic or extrasynaptic sites may have different effects on synaptic plasticity
and cellular signaling pathways.13,14 Although neuronal
survival is dependent on synaptic NMDA activity, excessive
excitatory neurotransmitter release activates extrasynaptic
receptors, which can be neurotoxic.11,15 Understanding the
dual nature of NMDA receptor function could allow for
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therapeutic targeting of speciﬁc prodeath signals, which if
identiﬁed and successfully blocked might have a therapeutic
effect with little impact on normal synaptic function.
Aside from their established role in immune system
functioning, the chemokine CXCL12 and its receptor CXCR4
(both constitutively expressed in the developing and adult
brains) have been implicated in neuronal survival in vitro and
in vivo.16 Recent studies have also suggested that this
chemokine may have important roles in both excitatory and
inhibitory neurotransmission.17,18 Our previous research19,20
indicates that CXCL12 rescues neurons exposed to excitotoxic insults by supporting the function of the retinoblastoma
protein (Rb), which is known to recruit transcriptional
repressors such as histone deacetylase (HDAC) to speciﬁc
promoters, including the promoter of the NR2B gene.21 Thus,
we hypothesized that CXCL12 may regulate the NMDA
receptor by modulating NR2B levels in the brain. The results
presented herein show that CXCL12 reduces NR2B expression both in vitro and in vivo and differentially affects neuronal
signaling triggered by selective stimulation of synaptic or
extrasynaptic NMDA receptors. This novel action of CXCL12
is not only consistent with a critical role of the CXCL12/CXCR4
axis in neuroprotection, but further expands the potential of
CXCL12 as a modulator of synaptic plasticity in the context of
epigenetic mechanisms.
Results
CXCL12 pretreatment induces long-term cellular
changes that protect cultured neurons from subsequent NMDA-induced neurotoxicity. We have previously
shown that CXCL12/CXCR4 positively regulates the
retinoblastoma protein Rb in neurons, thus inhibiting
NMDA-induced neurotoxicity.19 To further characterize the
mechanisms involved in CXCL12-mediated neuroprotection,
we examined whether pre-exposure of neuronal cultures to
CXCL12 protects neurons from a subsequent NMDA
stimulus. To this end, rat cortical neurons were incubated
with vehicle or CXCL12 (20 nM) for 24 h. After removing the
CXCL12-containing (or control) media, neurons were transiently exposed to toxic concentrations of NMDA (100 mM for

Figure 1 CXCL12 pretreatment prevents neuronal death and decreases
NMDA-induced intracellular calcium rise. CXCL12 (20 nM) or vehicle was added to
the culture media of rat cortical neurons 24 h before NMDA exposure, as described
in the ‘Materials and methods’ and ‘Results’ sections. (a) Cell survival was assayed
24 h after NMDA treatment (20 min, 100 mM). The graph shows NMDA-induced cell
death in cultures pretreated with vehicle, or CXCL12 (in the presence or absence
of the CXCR4 antagonist AMD3100); basal cell death in untreated neurons was
11.15±1.42, (mean±S.E.M., n ¼ 3), as indicated by the line in the graph.
AMD3100 (100 ng/ml) was added to the cultures 20 min before CXCL12 (*Po0.01,
ANOVA; CXCL12-treated signiﬁcantly lower than vehicle and AMD3100 þ
CXCL12). (b) CXCL12 pretreatment decreases calcium response stimulated by
NMDA (100 mM, 90 s). The effect was blocked by cotreatment with AMD3100
(100 ng/ml). Traces show average ratios (mean±S.E.M.) from at least 60 cells per
treatment analyzed individually (*Po0.05, ANOVA; CXCL12 signiﬁcantly lower
than vehicle and AMD3100 þ CXCL12). (c) Similar responses are observed with
lower NMDA concentrations (50 mM). (d) NMDA-induced (50 mM) calcium rise in the
absence (ﬁrst and second peak) and presence (third peak) of the L-type calcium
channel inhibitor nifedipine (5 mM)
Cell Death and Disease

20 min) and then returned to their regular culture media
(i.e., without CXCL12). Delayed NMDA-induced neurotoxicity
was evaluated the next day as reported previously.19,20,22
The results of these studies (Figure 1a) show that the extent
of neuronal cell death caused by NMDA was signiﬁcantly
reduced in neurons pretreated with CXCL12. As expected,
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the CXCR4 antagonist AMD3100 signiﬁcantly reduced the
neuroprotective action of CXCL12 (Figure 1a and
Supplementary Figure 1), in line with our previous report.19
These data indicate that stimulation of neuronal CXCR4 by
CXCL12 induces long-term cellular changes that protect
neurons from future excitotoxic insults.
Changes in intracellular calcium levels ([Ca þ 2]i) represent
a major event in determining the outcome of NMDA receptor
stimulation on neurons, as they dictate the nature of downstream signaling leading to survival or excitotoxicity.6
Thus, we examined the effects of CXCL12 pretreatment on
NMDA-induced [Ca þ 2]i changes in cortical neurons by using
fura-2-based single cell imaging. As previously reported,22 a
bath application of NMDA (50–100 mM) induces large calcium
responses in neurons indicated by an increase in the fura-2
ﬂuorescence ratio (340/380) (Figure 1b). Changes in NMDAinduced [Ca þ 2]i were quantiﬁed by measuring both peak
responses and area under the tracings. Figure 1b shows that
pre-exposure of neurons to CXCL12 signiﬁcantly reduces the
calcium rise evoked by NMDA. This effect of CXCL12 is
blocked by cotreatment with AMD3100, suggesting that
CXCR4 stimulation may regulate NMDA receptor function
(Figure 1b). However, recent studies have suggested that
short-term CXCL12 treatment can modulate voltage-sensitive
calcium channels under speciﬁc conditions.23 Therefore, to
establish whether this effect may contribute to the CXCL12
inhibition of NMDA-induced calcium response, the L-type
calcium channel blocker nifedipine was used. The results of
these experiments show that only a small portion (B10%) of
the NMDA-induced calcium rise can be attributed to activation
of voltage-sensitive calcium channels (Figure 1c and d), as
also reported by others.24 Thus, the effect of CXCL12 is likely
due to inhibition of the NMDA receptor. This conclusion was
conﬁrmed by additional studies (Supplementary Figure 2)
showing that CXCL12 pretreatment does not inhibit the
[Ca þ 2]i increase mediated by activation of voltage-sensitive
calcium channel, after exposure of neurons to high concentrations of extracellular potassium (KCl 25 mM).
CXCL12 downregulates NR2B subunit of the NMDA
receptor. Relative expression of NR2B is one of the
factors that contribute to calcium inﬂux through NMDA
receptors.25 Therefore, we sought to determine whether
CXCL12 could alter levels of NR2B in neurons. To answer
this question, we ﬁrst measured total protein levels of NR2B
after treatment of neurons with CXCL12 for increasing time
periods (1–24 h). As shown in Figure 2a and b, levels of
NR2B protein in CXCL12-treated neurons decreased in a
time- and AMD3100-dependent manner with signiﬁcant
changes becoming apparent after at least 3 h. No changes
in NR2A or NR1 protein levels are observed with the addition
of CXCL12 and/or AMD3100 (Supplementary Figure 3a).
Interestingly, CXCL12 also downregulates NR2B protein in
human neuronal cells (Supplementary Figure 3b). Next,
reverse transcriptase PCR (RT-PCR) was used to investigate the effect of CXCL12 on mRNA levels of different NMDA
receptor subunits (Figure 2c). To better evaluate the effect
of CXCL12 on the speciﬁc subunits, ampliﬁcation of each
subunit was performed with concurrent ampliﬁcation of the
housekeeping gene Aldolase A. As shown in Figure 2c,

treatment of rat cortical neurons with CXCL12 reduces levels
of NR2B transcripts but not of NR1 or NR2A. To further
conﬁrm and quantify this result, quantitative real-time PCR
was performed (Figure 2d). As expected, stimulation with
CXCL12 signiﬁcantly decreased the mRNA levels of NR2B
and no changes were observed in the NR1 subunit mRNA
levels (Figure 2d). Overall, these results show that activation
of the chemokine receptor by CXCL12 speciﬁcally decreases
expression of the NR2B subunit of the NMDA receptor in
post-mitotic neurons.
HDAC inhibitors prevent CXCL12 action. Our previous
study has shown that CXCL12 stimulates the generepression activity of Rb in neurons, and that this protein is
required for the neuroprotective role of CXCL12 against
NMDA toxicity.19 Importantly, Rb is involved in the neuronspeciﬁc repression complex calcium-responsive transactivation (CREST)–BRG1 that regulates activity-dependent
expression of the NR2B gene in cortical neurons.21 In
particular, transcriptional repression of NR2B involves
Rb-dependent, BRG1-mediated recruitment of HDAC1 to
the NR2B promoter.21 HDAC enzymes remove acetyl groups
from histone tails, thus altering histone/DNA interactions and
generally inhibiting gene transcription.26 Given the reported
effect of CXCL12 on Rb,19 this implies that the action of
CXCL12 on NR2B would depend on HDAC. To investigate
this hypothesis, we ﬁrst examined the effect of CXCL12 on
histone acetylation by measuring levels of acetylated histone
H3 (Figure 3a). As expected, CXCL12 reduced the levels of
acetylated histone in treated neurons, suggesting that the
chemokine positively regulates HDAC; in line with this result,
the broad-spectrum HDAC inhibitor Trichostatin A (TSA)
increased histone acetylation in sister cultures (Figure 3a).
Next, we examined the effect of CXCL12 on NR2B protein
levels in the presence of TSA and found that the downregulation of the NR2B subunit by CXCL12 was blocked by
cotreatment of neurons with the HDAC inhibitor (Figure 3b).
The effect of CXCL12 on the NMDA-induced calcium rise
was also blocked by cotreatment with TSA (Figure 3c).
Similar results were obtained with another, structurally
unrelated, HDAC inhibitor, that is, sodium butyrate (Supplementary Figure 4), which exhibits a different mechanism of
action compared with TSA. Overall, these data support the
notion that regulation of NR2B by CXCL12 is mediated by
physiological mechanisms involved in transcriptional repression of the NR2B gene, such as the CREST–BRG1 complex.
In vivo inhibition of CXCR4 increases NR2B protein
levels. Our next goal was to determine whether CXCL12/
CXCR4 activity in vivo regulates levels of NR2B subunit in a
similar manner to experiments conducted in neuronal
cultures. To this end, lactating mothers were administered
AMD3100 for four consecutive days, and the brains of pups
were collected 6 h after the last treatment with the CXCR4
antagonist. To determine whether CXCR4 was effectively
blocked in the brains of AMD-treated animals, two different
approaches were used. First, CXCL12-induced G-protein
activation was measured in the brain of control and
AMD3100-treated animals by in situ GTPgS incorporation
and autoradiography, as described previously.27 Second,
Cell Death and Disease
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Figure 2 CXCL12 treatment reduces levels of NR2B protein and mRNA but does not alter other NMDA subunits. (a) Addition of CXCL12 (20 nM, 1–24 h) to neuronal
culture media decreases NR2B protein levels in a time-dependent manner. Graph shows data from three independent experiments (*Po0.05 ANOVA; 3, 6, 24 h compared
with control) (b) The CXCR4 antagonist AMD3100 (100 ng/ml; added to cultures 20 min before CXCL12), blocked the effect of CXCL12 (20 nM) on NR2B protein levels. Bar
graph reports data from four independent experiments (*Po0.05 ANOVA; CXCL12 compared with all other groups). (c) mRNAs isolated from neuronal cultures treated with
CXCL12 (20 nM, 6 h) were analyzed by RT-PCR for NR2B, NR2A, or NR1 receptor levels. Separate gels were run for NR2A and AldoA because of close fragment lengths.
(d) qPCR studies were performed on control and CXCL12-treated neurons. The graph indicates relative changes in NR2B and NR1 levels normalized to the housekeeping
gene enolase 1 (*Po0.05 ANOVA; 15 h compared with control)

levels of the ligand-activated form of CXCR4, that is, CXCR4
phosphorylated on Ser339/8,28,29 were measured by
immunohistochemistry and western blot in the brain of
control and treated pups. The results show that AMD3100
treatment reduced both GTP ‘binding’ and pCXCR4 levels in
the pups’ brains (Figure 4a–c). Furthermore, the downregulation of CXCR4 function correlates with an increase in
the NR2B protein, which was measured in brain tissue
obtained from pups of the same litters (Figure 4d). These
experiments suggest that stimulation of CXCR4 by its endogenous ligand controls levels of NR2B protein in vivo.
Cell Death and Disease

CXCL12-induced regulation of NR2B subunit contributes to neuronal survival through the modulation of
extrasynaptic receptors. We used the NR2B-speciﬁc
antagonist RO-256981 to determine whether the
downregulation of the NR2B subunit by CXCL12
contributes to cell survival (Figure 5a). RO-256981 displays
high afﬁnity and speciﬁcity for NR2B-containing receptors
with a maximal effective concentration of 10 mM.30 It was
chosen over ifenprodil because of ifenprodil’s possible
nonspeciﬁc effects involving interactions with other
receptors or ion channels.30 In line with previous studies,
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RO-256981 reduces cell death induced by NMDA, signifying
a role for NR2B in NMDA excitotoxicity; this effect was
comparable with CXCL12 neuroprotection (Figure 5a).

Similar results were obtained in neurons cotreated with
RO-256981/CXCL12 (Figure 5a). As expected, on the basis
of previous studies,30 RO-256981 blocks the majority of
NMDA-induced calcium increase owing to its massive action
on NR2B-containing receptors, whereas the partial reduction
in NR2B protein levels caused by CXCL12 treatment leads to
less robust reduction in the NMDA-induced calcium rise
(Figure 5b). These data suggest that the reduction in NR2B
function has a role in CXCL12-mediated neuroprotection.
Furthermore, RO-256981 reduces NMDA calcium response
to a similar extent in control and CXCL12-treated neurons
(Figure 5b). Overall, these ﬁndings indicate that reduction in
NR2B-containing receptors by CXCL12 signiﬁcantly affects
NMDA-induced calcium signaling, thus contributing to
neuronal survival.
Several reports have indicated that overactivation of
NR2B containing NMDA receptors located extrasynaptically
may have a greater contribution to neurotoxicity.13,31 A high
proportion of extrasynaptic NMDA receptors have been
reported to contain NR2B subunits, and the activation of
these receptors is associated with an increase in cell mortality;
therefore, we next investigated the possibility that the
neuroprotective effect of CXCL12 could be associated
speciﬁcally with the regulation of extrasynaptic NR2B-containing receptors. To determine whether the downregulation of
the NR2B subunit contributes to extrasynaptic or synaptic
signaling, we used a well-characterized pharmacological
approach to record each response independently as previously reported by others.11 This protocol takes advantage
of the presence of GABAergic neurons that provide an
inhibitory tone to the culture system. Bicuculline, a GABAA
blocker, inhibits the intrinsic inhibitory synaptic GABA signaling inducing a physiological release of glutamate that in
turn activates synaptic receptors. Bicuculline applied with
4-aminopyridine (4-AP), a weak potassium channel blocker,
evokes transient calcium increases initiated by endogenous
glutamate-activating synaptic receptors.13 The ﬁrst calcium
response in Figure 6a illustrates the synaptic calcium
response induced by this protocol in control or CXCL12treated neurons. Selective activation of extrasynaptic receptors is achieved by ﬁrst blocking the synaptic response with
a coapplication of bicuculline/4-AP and the NMDA open
channel blocker MK801. Application of bicuculline/4AP with
MK801 ensures the selective blockage of the open synaptic

Figure 3 CXCL12 reduces global histone H3 acetylation in neurons, and
histone deacetylase (HDAC) inhibitors prevent the effects of CXCL12 on the NR2B.
(a) Global H3 acetylation levels were measured through a colorimetric acetylation
assay as indicated in the ‘Materials and methods’ section. Reduced levels of histone
acetylation were found in CXCL12-treated (20 nM) neurons compared with control;
this effect is blocked by cotreatment with TSA (100 nM) (*Po0.05 ANOVA;
CXCL12 compared with all other groups) (b) Changes in NR2B protein levels in
CXCL12- and/or TSA-treated neurons were analyzed by western blot. CXCL12
(20 nM) and/or TSA (100 nM) were added to neuronal culture media for 24 h; the bar
graph reports the band density normalized to actin from three independent
experiments (*Po0.05 ANOVA; CXCL12 compared with all other groups). (c) Fura-2
studies indicate that TSA (100 nM) treatment abolished the effect of CXCL12
(20 nM) on NMDA-induced (100 mM) calcium responses. Data in the bar graph are
reported as changes in the 340/380 ratios (i.e., from baseline to peak); at least 20
cells per treatment were analyzed from three independent experiments (*Po0.05
ANOVA; CXCL12 compared with all other groups)
Cell Death and Disease
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Figure 4 In vivo AMD3100 administration increases NR2B protein levels in the rat cortex. (a) AMD3100 treatment decreases CXCR4 phosphorylation in brain slices of
treated animals as detected through immunohistochemistry, using phospho-speciﬁc antibodies against ligand-activated CXCR4. Three animals per group were analyzed and
no changes were observed in total levels of CXCR4. (b) Studies in homogenized tissue samples (cerebral cortex and hippocampus) also show a reduction in phosphorylated
levels of CXCR4 compared with total CXCR4 (*Po0.05 Student’s t-test). The graph reports averaged data obtained from eight animals per group (representative immunoblot
on the top). (c) AMD3100 pretreatment in vivo decreases [35S] GTPgS incorporation after stimulation of brain slices with CXCL12. Analysis was performed in different brain
areas as previously reported:27 medial cortex (MC) and lateral cortex (LC). Three animals per treatment group were analyzed (*Po0.05 Student’s t-test; AMD3100 compared
with control in each brain region). (d) In vivo AMD3100 (1.25 mg/kg) treatment decreases NR2B protein levels in brain tissue (cerebral cortex and hippocampus) collected from
P4 pups and analyzed by western blot. In all, 11 animals per treatment group were analyzed (*Po0.05 Student’s t-test)

receptors, which is illustrated by the second calcium response
in Figure 6a. Finally, the extrasynaptic NMDA receptors are
activated with a bath application of NMDA and depicted by the
large calcium transient in the third part of Figure 6a. These
Cell Death and Disease

paradigms were used to dissect the synaptic from the
extrasynaptic calcium response. Neurons pretreated with
CXCL12 exhibit a signiﬁcant reduction in the extrasynaptic
NMDA-induced calcium rise compared with control cells
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increases ERK phosphorylation exclusively by synaptic
receptor activity.35 Furthermore, activation of extrasynaptic
NMDA receptors containing NR2B subunits inactivates ERK
by increasing the rate of dephosphorylation.15 Consistent
with these ﬁndings, pretreatment of neurons with CXCL12
enhances ERK activation after bicuculline/4-AP treatment as
compared with vehicle-treated neurons (Figure 7a). This is
also in agreement with the effect of CXCL12 on synaptic/
extrasynaptic calcium responses (Figure 6), and suggests
that the CXCL12 reduction of extra-synaptic NR2B receptors
blocks ERK inactivation signal. In addition, CXCL12 may
prolong NMDA synaptic activity, further promoting ERK
phosphorylation as suggested by our previous calcium
imaging results. Interestingly, activation of synaptic and
extrasynaptic glutamate receptors leads to separate geneexpression proﬁles and synaptic receptor activation generally
increases expression of prosurvival genes, including
CXCR4.31 In line with these recent ﬁndings, we observe an
increase in protein levels of CXCR4 following the synaptic
activation protocol (Figure 7b). The ability of CXCL12 to
regulate ERK activation and its downstream signaling
triggered by the release of endogenous neurotransmitter
indicates an important role of the chemokine in neuronal
survival.
Discussion

Figure 5 Effect of CXCL12 and RO-256981 on neuronal survival and NMDAinduced calcium changes. (a) CXCL12 (20 nM, 24 h) and the NMDA antagonist
RO-256981 (10 mM, 24 h) independently protect neurons from NMDA treatment
(*Po0.05 ANOVA; NMDA-treated compared with basal and all other treatment
groups). (b) Calcium imaging studies show that RO-256981 markedly reduces
NMDA-induced intracellular calcium rise both in control and CXCL12-treated
neurons. The graph shows average calcium responses (mean±S.E.M.; B20 cells
per group)

(Figure 6b). Interestingly, CXCL12 also induces a small
increase in the duration of the synaptic response but has no
effect on the peak level of intracellular calcium elicited by the
synaptic protocol (Figure 6c and d), indicating that CXCL12
does not impair calcium transients induced by activation of
synaptic receptors. These data correlate with reports that
extrasynaptic NMDA receptor activation has a greater
contribution to excitotoxicity, and our hypothesis that CXCL12
promotes neuronal survival by reducing the presence of
NR2B-containing receptors, which are mainly expressed at
extrasynaptic levels in mature neurons.9,32,33
CXCR4 activation enhances synaptic signaling to the
nucleus. Synaptic and extrasynaptic receptors seem to
have distinct roles in neuronal survival in part by
differentially activating signaling cascades. To study the
effect of CXCL12 on survival signaling pathways stimulated
by synaptic activation, we determined whether exposure to
CXCL12 alters the extracellular-regulated kinase (ERK)
response to NMDA. In neurons, ERK signaling mediates a
key step in regulatory pathways involved in cell survival.34
Recent data indicate that NMDA receptor activation

CXCL12 and its receptor CXCR4 are expressed on neuronal
and glial cells and control different processes involved in the
development of the central nervous system (CNS) and
inﬂammatory responses, such as cell migration and differentiation. Recent evidence has suggested that this chemokine/receptor pair may also contribute to homeostasis of the
mature brain by regulation of cell survival and synaptic
transmission.36,37 In line with this contention, in this study,
we provide evidence of a novel mechanism that further
implicates CXCL12 in the regulation of synaptic activity and
neuronal signaling. Our results show that CXCL12/CXCR4
modulates the expression of NR2B, a critical subunit of the
glutamate NMDA receptor, which is known to inﬂuence
synaptic maturation, plasticity, and neuronal viability. Importantly, NR2B downregulation by CXCL12 is associated with
a speciﬁc reduction in excitotoxic calcium responses and
activation of extrasynaptic NMDA receptors; conversely,
prosurvival responses coupled to stimulation of NMDA
receptors located at the synaptic level seem to be facilitated
by CXCL12, as shown by enhanced ERK activation following
synaptic receptor activation in CXCL12-treated neurons. ERK
signaling cascade is associated with spine formation, longterm potentiation, and neuronal survival.38 Recent studies
have shown that ERK signaling is activated by synaptic NMDA
receptors, and that stimulation of extrasynaptic receptors
leads to ERK dephosphorylation/inactivation.15 CXCL12induced reduction in the extrasynaptic signal potentially
blocks ERK dephosphorylation, which results in enhanced
levels of pERK and cell survival. We also ﬁnd that
protein levels of CXCR4 are increased after synaptic NMDA
receptor activation; this is relevant in view of the observation
that synaptic activation upregulates functionally related
genes contributing to neuronal survival.31 Therefore,
Cell Death and Disease
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Figure 6 CXCL12 selectively decreases calcium responses induced by stimulation of NMDA extrasynaptic receptors. (a) Control neurons and CXCL12 pretreated
neurons were stimulated with bicuculline (50 mM) and 4-AP (2.5 mM) to evoke a synaptic response, followed by a coapplication of bicuculline, 4-AP, and MK801 (10 mM) to
speciﬁcally and irreversibly block the synaptic NMDA receptors response. The following NMDA stimulation represents the extrasynaptic response induced by a bath application
of NMDA (50 mM). These experiments indicate a dramatic reduction in extrasynaptic response (graph b) and modest stimulation in synaptic responses (graphs c and d). Data
obtained from three or more independent experiments; a total of at least 45 neurons per group were studied (*Po0.05)

Figure 7 CXCL12 treatment enhances ERK activation stimulated by synaptic NMDA receptor activation. (a) Effect of CXCL12 on ERK activation after treatment with
bicuculline and 4-AP, as reported above. Phospho-ERK immunoreactivity was normalized to total ERK, and the bar graph represents band density as a percentage of control
from four independent experiments. (*Po0.05 ANOVA; 5 and 15 min Bic/4AP-treated in CXCL12 group compared with control). (b) Selective activation of synaptic glutamate
receptors by application of bicuculline and 4-AP for the indicated time increases CXCR4 protein levels in a time-dependent manner. Bar graph reports average data from three
independent experiments (*Po0.05 ANOVA; 4 and 6 h versus control)

CXCL12/CXCR4 may be involved in this positive feedback
loop. Our data are also in agreement with reports showing
predominant expression of NR2B at extrasynaptic sites in
Cell Death and Disease

differentiated neurons33 and the potential different contribution of NR2B- and NR2A-containing receptors to neurotoxicity.39 In addition, as during development NR2B is gradually
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replaced by NR2A at synaptic sites, CXCL12 may also
contribute to synaptic maturation in developing neurons.
However, further experiments are necessary to conﬁrm the
latter conclusion. Overall, our data show for the ﬁrst time that
CXCL12 induces long-term adaptive changes that ultimately
modulate NMDA receptor functions. This hypothesis was
initially suggested by our previous studies showing that
CXCL12 positively regulates the gene repression (and
neuroprotective) function of Rb,19 and is in agreement with
the recently reported role of Rb and HDAC1 in the inhibition of
NR2B expression by the CREST–BRG1 repressor complex.21
Thus, CXCL12-mediated regulation of NR2B expression
contributes to the complex neurotrophic role of the chemokine
in the CNS. Notably, the changes in NR2B levels observed in
the brain of AMD-treated animals suggest that these
mechanisms are also effective in vivo.
Given the role of HDAC in NR2B repression, we started
investigating the potential of CXCL12 to act as an epigenetic
modulator through regulation of histone-modifying enzymes,
such as HDAC. Removing acetyl moieties from histone makes
them more positively charged causing a greater association
with the negatively charged DNA, which ultimately leads to
gene repression. The data reported in this study show that
CXCL12 decreases overall levels of acetylated histone H3,
and ongoing studies suggest that the chemokine may regulate
certain isoforms of HDAC (such as HDAC4) that shuttle from
the cytosol to the nucleus depending on synaptic activity. If
conﬁrmed, these results would suggest that CXCL12 could
alter the expression of a number of activity-dependent genes,
which is currently under investigation by a separate study.
The effects of TSA in terms of NR2B expression and
NMDA-induced calcium changes are in apparent contrast
with the reported neuroprotective action of general HDAC
inhibitors. However, such neuroprotective action of HDACi
has often been reported in the context of genetic disorders,
suggesting that the effect of HDACi in these circumstances
may be primarily related to the regulation of mutated/altered
genes, with recovery of the normal phenotype. Moreover,
HDACi may regulate speciﬁc survival genes, such as p21,40
which would result in different outcomes depending on the
involvement of such genes in the injury model. Indeed,
neurotoxic effects of broad-spectrum HDAC inhibitors have
also been reported,40,41 and little is known about the
consequences of prolonged inhibition of HDAC. It is becoming
more and more clear that potential long-term side effects of
general HDAC inhibition may limit therapeutic tolerance, and a
better understanding of speciﬁc gene regulation by epigenetic
modulators is required. Finally, contributions of speciﬁc HDAC
isoforms to neuronal survival, their regulation by neurotrophins, and the role of additional histone/DNA modiﬁcations
will have to be established to generate more effective
therapeutics. Thus, future combined efforts are required to
fully address these issues.
In conclusion, this study provides the ﬁrst evidence that
CXCL12 affects NMDA receptors by regulating expression
of the NR2B subunit – which has important implications to
neuronal signaling and plasticity in both developing and
mature neurons, and is highly relevant to a large spectrum of
neurological disorders. This study and our previous ﬁndings19
collectively suggest that the effect of CXCL12 on NR2B

involves physiological mechanisms of gene repression21
that are currently been exploited for therapeutic purposes,
emphasizing the impact of this research in different ﬁelds.
Materials and Methods
Cell culture. Primary neurons were obtained from the cerebral cortex of
embryonic day 17 (E17)/E18 rat embryos and cultured in the Neurobasal medium as
reported previously.28 To further reduce the growth of non-neuronal cells, cytosine
arabinoside (1 mM) was added to the cultures. This leads to a virtually glia-free
culture (495% neurons) as assessed by expression of neuronal and non-neuronal
markers.28 Brieﬂy, neurons were plated at a density of 900 000 cells per well of a
6-well plate in the Neurobasal medium containing B27 (2%) and horse serum (2%).
The medium was replaced 2 h after plating with serum-free Neurobasal medium
supplemented with B27, L-glutamine (0.5 mM), glutamic acid (25 mM) (Tocris
Bioscience), and 10 mg/ml gentamycin. On the fourth and eighth day in vitro (DIV),
the culture medium was replaced again with the Neurobasal media supplemented
with B27, L-glutamine, and gentamycin. On the fourteenth day of culture, half of
the media were changed with the Neurobasal media supplemented with B27,
L-glutamine, and gentamycin. Neurons were used between DIV 16 and 20.
Human neuronal cell line, SH-SY5Y, was acquired from the ATCC. Cells
were cultured in media containing 10% FBS, 45% MEM, and 45% F-12.
Culture media were changed every 3 days and cells were split when they reached
B85% conﬂuency.
Western blots. Primary neurons were washed with ice-cold phosphatebuffered saline (PBS), collected in lysis buffer (150 mM NaCl, 50 mM Tris, 0.5% Na
deoxycholate, 0.1% SDS, 10 mM Na4P2O7, 5 mM EDTA, 1% Triton X-100, and
protease and phosphatase inhibitor mixture), and then incubated for 30 min at 41C
as reported previously.19,20,28 Lysates were spun (14 000 r.p.m. for 10 min) in an
Eppendorf 5417R microcentrifuge, and the protein concentration of the
supernatants was determined using bicinchoninic acid protein assay following the
instructions of the manufacturer (Pierce). Equal amounts of protein (20 mg per lane)
were loaded for SDS-PAGE, followed by immunoblotting. The following antibodies
were used: anti-NR2B (1 : 1000) (R&D, Alomone), anti-actin (1 : 1000) (SigmaAldrich), anti-pERK (1 : 1000), and total ERK (1 : 1000) (Cell Signaling Technology).
Bands were detected by Pierce chemiluminescence reagents (SuperSignal West
Femto maximum sensitivity) and analyzed using the image detection and analysis
system from Alpha Innotech, FluorChem 8900 (San Leandro, CA, USA). Values
from actin or total ERK were used to verify equal loading and for normalization.
Brain tissue homogenates (the cortex and hippocampus) were washed once with
PBS and incubated in lysis buffer on ice for 20 min, followed by centrifugation at
28 000 for 20 min. The protein concentration was measured and equal amounts of
protein were used for SDS-PAGE, followed by immunoblotting with antibodies
against pCXCR4 S339 (1 : 1000),29 CXCR4 (1 : 1000; Abcam), and NR2B (1 : 1000
Alomone).
Survival assays. Neurons were plated on glass coverslips (15 mm diameter) at
a density of 35 000 cells per coverslip. CXCL12 (20 nM) was added to neuronal
culture medium for 24 h and then washed with PBS solution. Neurons were returned
to a magnesium-free saline solution (157 mM NaCl, 5 mM KCl, 0.64 KH2PO4, 3 mM
NaHCO3, 5 mM glucose, 20 mM HEPES, 0.33 mM Na2HPO4) containing 2 mM
CaCl2 and treated with NMDA for 20 min. Cells were washed again with PBS and
fresh culture media were added. Survival was assayed 24 h after NMDA treatment
with a combination of propidium iodine (10 mm/ml)/ﬂuorescein diacetate (10 mg/ml)/
Hoescht 3342 staining (5 mg/ml) as reported previously.19,20 Ten random ﬁelds per
coverslip and three coverslips per treatment were analyzed for each independent
experiment. Results are expressed as a percentage of dead cells. Approximately
200 cells per treatment group were used.
Calcium imaging. Neurons plated on glass coverslips (15 mm) and cultured
as described above were loaded with 2 mM fura-2 AM (Molecular Probes) for
20 min (r.t.), washed with saline solution (157 mM NaCl, 5 mM KCl, 0.4 mM MgSO4
0.5 mM MgCl2, 0.64 KH2PO4, 3 mM NaHCO3, 5 mM glucose, 20 mM HEPES,
0.33 mM Na2HPO4, 2 mM CaCl2) and re-incubated for an additional 20 min at
room temperature as described previously.22 During the experiments, cells were
perfused with an external magnesium-free saline solution (157 mM NaCl, 5 mM
KCl, 0.64 KH2PO4, 3 mM NaHCO3, 5 mM glucose, 20 mM HEPES, 0.33 mM
Na2HPO4) containing 2 mM CaCl2. Each cell in the ﬁeld was analyzed
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independently. NMDA-induced calcium rises recorded from individual cells were
quantiﬁed by peak responses (calculated as the difference between peak response
and pre-stimulus baseline) and area under the traces. Extrasynaptic and synaptic
responses were isolated following a protocol published by Leveille et al. (2008).
Brieﬂy, synaptic responses were evoked with the application of bicuculline (50 mM)
and 4-AP (2.5 mM), whereas extrasynaptic responses were isolated through
blocking the synaptic response with MK801 (10 mM) in addition to bicuculline and
4-AP. The following NMDA stimulation evoked the extrasynaptic NMDA response.
RNA extraction and RT-PCR. Total RNA was extracted using the RNeasy
mini kit (Qiagen) as reported previously.19,20 The RNA quality and concentration
were assessed using the NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies). Samples with optical density 260/280 and 260/230 ratios of X1.8
were used for PCR studies. Random hexamers were used to synthesize cDNAs.
The following primers were used to amplify NR2B, NR1, or Aldolase A: NR2B,
50 -GGATCTACCAGTCTAACATG-30 and 50 -GATAGTTAGTGATCCCACTG-30 ;
NR1, 50 -TACACTGCCAACTTGGCAGCTTTC-30 and 50 -CATGAAGACCCCTGC
CATGTT-30 . For rat Aldolase A, the following primers were used: 50 -AACCAATG
GCGAGACCACTAC-30 and 50 -AATTTCAGGCTCCACAATGG-30
qPCR. Total RNA was isolated from control or CXCL12 (20 nM)-treated primary
rat cortical neurons. cDNA was synthesized as mentioned above. Ampliﬁcation was
performed with Taqman PCR master mix (Applied Biosystems, Foster City, CA,
USA) on ABI PRISM 7300 Sequence detection system (Applied Biosystems) as
reported in Khan et al. (2008). Brieﬂy, the thermal cycle proﬁle for all transcripts was
as follows (the reaction initiated at 951C for 15 min). A total of 40 PCR cycles were
performed with 30 s of denaturing at 951C then 30 s at 551C for annealing and 30 s
at 721C for extension. After ampliﬁcation, a melting-curve analysis of the ampliﬁed
DNA was performed. A standard curve for each gene was generated to determine
the linear range and ampliﬁcation efﬁciency. The LLCT method was used to
analyze the data. Levels of NR1 or NR2B were expressed relative to fold change
after normalization to that of the housekeeping gene Enolase. Real-time PCR
quantiﬁcation was performed in triplicate from three separate experiments.
Histone acetylation assay. Histone H3 acetylation was measured using
the EpiQuick Global Histone H3 acetylation assay kit following the manufacturer’s instructions (Epigentek). Brieﬂy, nucleic fraction was isolated and
histones were extracted from cell lysates. Histone proteins were then stably spotted
on microplate strip wells by incubating wells at 371C for 90 min. The primary
antibody to detect acetylated histone was incubated for 1 h at room temperature.
The amount of aceylated histone was detected by HRP-conjugated
secondary antibody and quantiﬁed through a colorimetric reaction by the
microplate reader.
In vivo AMD3100 Administration and GTPcS Autoradiography. AMD3100 (Sigma-Aldrich) was dissolved in physiological saline (PBS)
and injected intraperitoneally (IP) 1.25 mg/kg to lactating Holtzmann rat beginning
1 day after giving birth. The lactating mother was injected one time per day for four
consecutive days. Rat pups postnatal days 5 (P5) were killed 6 h after the last
injection to the mother. The brains of the pups were rapidly removed, quickly frozen,
and stored at 801C. [35S] GTPgS autoradiography was performed on coronal
sections as described previously.27 Brieﬂy, 20-mM sections mounted onto slides
were pre-incubated in slide mailers for 40 min at 251C in assay buffer (in mM: 50
Tris-HCl, 4 MgCl2, 0.3 EGTA, and 100 NaCl; pH7.4), followed by 20 min incubation
in 2 mM GDP in assay buffer. Sections were then incubated for 2 h at 251C in assay
buffer containing [35S] GTPgS (0.04 nM, 1250 ci/mmol) and 2 mM GDP. After
incubation, sliders were rinsed twice in cold Tris-HCl (50 mM) and then brieﬂy in cold
deionized water, dried immediately with a cool stream of air, and desiccated
overnight. Slides were exposed to Kodak Biomax MS ﬁlm (Eastman Kodak) for 48 h.
Images from the developed ﬁlms were scanned and quantiﬁed using Image
Pro-Plus Version 4.5 software (MediaCybernetics).
Immunohistochemistry. Immunohistochemical analysis was performed as
described previously.20,28 Brieﬂy, 20-mM sections were stored at 201C for 24 h
and then air dried at room temperature for 60 min. Sections were then ﬁxed for 2 min
with acetone at room temperature. Before incubation with primary antibody, the
sections were blocked in normal donkey serum, 1 : 250 diluted with 1  Trisbuffered saline (TBS, pH7.4). The sections were then incubated overnight with
primary antibody pCXCR4 (1 : 50) and CXCR4 (1 : 50) diluted in 1  TBS with 2.5%
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normal donkey serum. After washing three times with 1  TBS, sections were
incubated with HRP anti-rabbit secondary antibody (Jackson Immuno Research)
and 1 : 250 diluted in 1  TBS with 2.5% normal donkey serum for 2 h at room
temperature. Reaction products were visualized by the avidin–biotin peroxide
complex method (Vector Laboratories). Negative controls were processed in a
similar manner without the addition of the primary antibody.
Statistical analysis. Each graph reports the mean±S.E.M. of three to four
independent experiments unless otherwise noted. Student’s t-test or one-way
ANOVA, followed by Newman-Keuls post hoc test were used for statistical analysis.
A Po0.05 or less was considered signiﬁcant.
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